ReCode Therapeutics key facts
as of Oct 2026- Developer of targeted delivery technology designed for patients with rare diseases.
- ReCode Therapeutics is valued at approximately $700.0M as of Oct 2026, set at its later-stage round, Sep 2023; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $388.0M across 3 recorded rounds; the latest was Debt ($29.4M) in Sep 2025.
- Notable investors include Evolution VC Partners, OrbiMed, Osage University Partners, Blockchange Ventures, Pfizer Ventures — 24 tracked in total.
- ReCode Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently Sep 2023 ($259.8M sold to 28 investors).
- Status: Privately Held (backing).
Valued at $700.0M at its later-stage round, Sep 2023. Nothing has traded since.
- ·The complete investor list: 24 names
- ·Watch ReCode Therapeutics: the Monday email on marks, rounds and moves
ReCode Therapeutics funding rounds
3 roundsWho backs ReCode Therapeutics
24+ReCode Therapeutics valuation
ReCode Therapeutics was valued at $700 million at its later-stage round in Sep 2023. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has ReCode Therapeutics raised?
ReCode Therapeutics has raised $388 million across 3 recorded rounds since 2020. The largest was a $29.4 million debt round in Sep 2025.
ReCode Therapeutics has filed 5 Form Ds with the SEC since 2020, most recently in Sep 2023 ($260 million sold to 28 investors).
ReCode Therapeutics investors
24 investors are on record for ReCode Therapeutics, including Evolution VC Partners, OrbiMed, Osage University Partners and Blockchange Ventures. By type, the record holds 4 venture capital firms, 3 hedge funds and 1 growth equity firm. The debt round in Sep 2025 drew 26 investors.
About ReCode Therapeutics
Developer of targeted delivery technology designed for patients with rare diseases. The company's platform utilizes lipid nanoparticles to precisely deliver corrective or disease-modifying genetic therapies to specific organs and tissues, potentially overcoming limitations of current gene therapy methods and offering new hope for patients with unmet medical needs, enabling healthcare firms with life-limiting respiratory diseases to avail themselves of medicines.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2015
- Employees
- 105
- Website
- recodetx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.